These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28481019)

  • 1. The frequency of occurrence of atypical lymphocytes in peripheral blood smears of natalizumab-treated patients with multiple sclerosis.
    Robier C; Amouzadeh-Ghadikolai O; Bregant C; Diez J; Melinz K; Quehenberger F; Quasthoff S
    Int J Lab Hematol; 2017 Oct; 39(5):469-474. PubMed ID: 28481019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
    Plavina T; Muralidharan KK; Kuesters G; Mikol D; Evans K; Subramanyam M; Nestorov I; Chen Y; Dong Q; Ho PR; Amarante D; Adams A; De Sèze J; Fox R; Gold R; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Hartung HP; Cree BAC
    Neurology; 2017 Oct; 89(15):1584-1593. PubMed ID: 28916537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.
    Koudriavtseva T; Sbardella E; Trento E; Bordignon V; D'Agosto G; Cordiali-Fei P
    Clin Exp Immunol; 2014 Jun; 176(3):320-6. PubMed ID: 24387139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients.
    Carotenuto A; Scalia G; Ausiello F; Moccia M; Russo CV; Saccà F; De Rosa A; Criscuolo C; Del Vecchio L; Brescia Morra V; Lanzillo R
    J Neuroimmunol; 2017 Aug; 309():47-50. PubMed ID: 28601287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis.
    Petersen ER; Søndergaard HB; Oturai AB; Jensen P; Sorensen PS; Sellebjerg F; Börnsen L
    Mult Scler Relat Disord; 2016 Nov; 10():66-72. PubMed ID: 27919501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab.
    Dallari S; Franciotta D; Carluccio S; Signorini L; Gastaldi M; Colombo E; Bergamaschi R; Elia F; Villani S; Ferrante P; Delbue S
    J Neuroimmunol; 2015 Oct; 287():76-9. PubMed ID: 26439965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythroblastaemia in natalizumab-treated patients with multiple sclerosis.
    La Gioia S; Seghezzi M; Barcella V; Dominoni P; Mecca T; Frigeni B; Conti MZ; Vedovello M; Vidali M; Rottoli M; Buoro S
    Mult Scler Relat Disord; 2016 Jul; 8():141-4. PubMed ID: 27456890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis.
    Robier C; Amouzadeh-Ghadikolai O; Bregant C; Diez J; Melinz K; Neubauer M; Quasthoff S
    Mult Scler; 2014 Aug; 20(9):1269-72. PubMed ID: 24493472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune surveillance in multiple sclerosis patients treated with natalizumab.
    Stüve O; Marra CM; Jerome KR; Cook L; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Hemmer B; Monson NL; Racke MK
    Ann Neurol; 2006 May; 59(5):743-7. PubMed ID: 16634029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Matrix Metalloproteinases Panel in Multiple Sclerosis Patients Treated with Natalizumab: A Possible Answer to Natalizumab Non- Responders.
    Balasa R; Bianca C; Septimiu V; Iunius S; Adina H; Sebastian A; Andreea R; Anca M; Smaranda M
    CNS Neurol Disord Drug Targets; 2018; 17(6):464-472. PubMed ID: 29968546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients.
    Teniente-Serra A; Grau-López L; Mansilla MJ; Fernández-Sanmartín M; Ester Condins A; Ramo-Tello C; Martínez-Cáceres E
    Autoimmunity; 2016 Jun; 49(4):219-28. PubMed ID: 26829210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
    Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
    Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
    Johnson BH; Bonafede MM; Watson C
    CNS Drugs; 2015 Jun; 29(6):503-10. PubMed ID: 26113055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients.
    Iaffaldano P; Viterbo RG; Trojano M
    J Neurol; 2016 Aug; 263(8):1620-5. PubMed ID: 27260295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment.
    Bühler U; Fleischer V; Luessi F; Rezk A; Belikan P; Graetz C; Gollan R; Wolf C; Lutz J; Bar-Or A; Siffrin V; Zipp F
    Mult Scler; 2017 Apr; 23(4):567-576. PubMed ID: 27436357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
    Kohlmann R; Salmen A; Chan A; Knabbe C; Diekmann J; Brockmeyer N; Skaletz-Rorowski A; Michalik C; Gold R; Überla K
    Mult Scler; 2015 Dec; 21(14):1823-32. PubMed ID: 25828755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of naïve, memory and effector T cells in progressive multiple sclerosis.
    Nielsen BR; Ratzer R; Börnsen L; von Essen MR; Christensen JR; Sellebjerg F
    J Neuroimmunol; 2017 Sep; 310():17-25. PubMed ID: 28778440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphocytes in the treatment with interferon beta-1 b.
    Pavelek Z; Vyšata O; Klímová B; Andrýs C; Vokurková D; Vališ M
    Mult Scler Relat Disord; 2017 Nov; 18():29-32. PubMed ID: 29141817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis.
    Kivisäkk P; Francois K; Mbianda J; Gandhi R; Weiner HL; Khoury SJ
    PLoS One; 2014; 9(7):e103716. PubMed ID: 25075741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.